Literature DB >> 27849419

Short-term Intensive Immunosuppression: A Randomized, Three-arm Study of Intravenous Pulse Methylprednisolone and Cyclophosphamide in Macular Serpiginous Choroiditis.

Pradeep Venkatesh1, Akshay Tayade2, Varun Gogia1, Shikha Gupta2, Bhavin M Shah2, Rajpal Vohra1.   

Abstract

PURPOSE: To compare the efficacy of pulse cyclophosphamide with pulse dexamethasone in acute macular serpiginous choroiditis (SC).
METHODS: A total of 30 patients with macular SC were prospectively randomized into three treatment groups: group D (pulse dexamethasone); group C (pulse cyclophosphamide); and combination (pulse group DCP) administered for 3 days. Macular SC was defined as any active lesion involving/threatening macula.
RESULTS: A total of 30 patients were enrolled, with 10 patients in each group. Lesions completely healed at median duration of 2 weeks in each group, with significant improvement in visual acuity compared with pretreatment levels (p<0.05). Pulse cyclophosphamide was most effective in faster healing of lesions compared with other groups. There was no difference in gain in visual acuity between any of the groups (p = 0.32).
CONCLUSIONS: Cyclophosphamide may be an effective treatment modality for acute macular SC, though it may not have a long-term effect on disease relapse.

Entities:  

Keywords:  Cyclophosphamide; immunosuppression; pulse dexamethasone; serpiginous choroiditis

Mesh:

Substances:

Year:  2016        PMID: 27849419     DOI: 10.1080/09273948.2016.1237663

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  4 in total

Review 1.  Mechanisms, Pathophysiology and Current Immunomodulatory/Immunosuppressive Therapy of Non-Infectious and/or Immune-Mediated Choroiditis.

Authors:  Ioannis Papasavvas; Ilknur Tugal-Tutkun; Carl P Herbort
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-24

Review 2.  Enigma of serpiginous choroiditis.

Authors:  Parthopratim Dutta Majumder; Jyotirmay Biswas; Amod Gupta
Journal:  Indian J Ophthalmol       Date:  2019-03       Impact factor: 1.848

Review 3.  Tuberculosis-related serpiginous choroiditis: aggressive therapy with dual concomitant combination of multiple anti-tubercular and multiple immunosuppressive agents is needed to halt the progression of the disease.

Authors:  Ioannis Papasavvas; Bruno Jeannin; Carl P Herbort
Journal:  J Ophthalmic Inflamm Infect       Date:  2022-02-08

4.  Chlorambucil combination therapy in refractory serpiginous choroiditis: A cure?

Authors:  Arash Maleki; Anapatricia Maldonado Cerda; Cristina M Garcia; Mike Zein; Ambika Manhapra; C Stephen Foster
Journal:  Am J Ophthalmol Case Rep       Date:  2021-01-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.